Navigation Links
Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
Date:8/11/2011

dvancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

About NUEDEXTA

NUEDEXTA® is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias. The primary outcome measure, laughing and crying episodes, was significantly lower in the NUEDEXTA arm compared to placebo. The secondary outcome measure, the Center for Neurologic Studies Lability Scale (CNS-LS), demonstrated a significantly greater mean decrease in CNS-LS score from baseline for the NUEDEXTA arm compared to placebo.

NUEDEXTA Important Safety Information

NUEDEXTA can interact with other medications causing significant changes in blood levels of those medications and/or NUEDEXTA. NUEDEXTA is contraindicated in patients rec
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 The Chinese wound ... population and rise in the incidence of lifestyle diseases, ... and in affordability of better quality of wound care ... market. Universal coverage of public health insurance schemes and ... stimulate demand. Based on the findings of primary and ...
(Date:9/30/2014)... Quebec , Sept. 30, 2014 Valeant ... TSX: VRX) today announced that the company,s ... Letter from the U.S. Food and Drug Administration (FDA) ... Company,s records with regards to Sculptra Aesthetic injectable, which ... Warning Letter pertains to the management of Valeant,s contract manufacturers ...
(Date:9/30/2014)... Sept. 30, 2014 The signing of ... and New Jersey Health Foundation (NJHF) to work ... care programs has been announced by Rodger ... Kessler Foundation and James M. Golubieski , ... "The experience of New Jersey Health Foundation in ...
Breaking Medicine Technology:China Wound Care Market 2China Wound Care Market 3Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2
... 2007 - Reata,Pharmaceuticals, Inc. today announced the ... Synthetic Triterpenoid programs in,the May 2007 issue ... article, "Triterpenoids and rexinoids as multifunctional,agents for ... researchers,and Reata scientific collaborators from the Dartmouth ...
... least,one-third of the time, the symptoms of bipolar ... children, it can be,difficult to distinguish bipolar symptoms ... issue of the Harvard Mental Health,Letter. , Children, ... cycle of distinct mood episodes of mania and ...
Cached Medicine Technology:Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 2Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 3Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 4Bipolar Disorder in Children Difficult to Diagnose, Reports the,Harvard Mental Health Letter 2
(Date:9/30/2014)... Palm Beach, Florida (PRWEB) September 30, 2014 ... the No. 1 selling beauty brand on Amazon.com. , ... Sellers in their respective beauty categories on Amazon.com,” said Craig ... available in the UK on Amazon.co.uk and Canada on Amazon.ca ... latest products, which just launched earlier last month, are already ...
(Date:9/30/2014)... of Dental Medicine have been awarded a $11.8 million, ... Craniofacial Research, part of the National Institutes of Health, ... cleft lip and cleft palate and to expand the ... and Pennsylvania. , Orofacial clefts (OFCs), which are ... form when a baby,s mouth doesn,t develop properly during ...
(Date:9/30/2014)... of Michigan are pleased to announce an agreement to ... and Endocrinology , which is now open for submissions ... 2015. , The journal is led by Editor-in-Chief, ... of Metabolism, Endocrinology, and Diabetes, at the University of ... an international Editorial Board. , Clinical Diabetes ...
(Date:9/30/2014)... as an unusual character from a "Seinfeld" episode or ... genetic disease called SCID, short for severe combined immunodeficiency, ... contact because their bodies, natural defenses are too weak ... than 2,000 new births each year worldwide, SCID is ... a human immunodeficiency virus HIV/AIDS. , Now, using ...
(Date:9/30/2014)... and cardiac muscles contain few stem cells, heart ... heart attack. Now Tel Aviv University researchers are ... tissue engineering. , Dr. Tal Dvir and his ... Biotechnology, Department of Materials Science and Engineering, and ... sophisticated micro- and nanotechnological tools ranging in ...
Breaking Medicine News(10 mins):Health News:OZ Naturals Now the No. 1 Selling Beauty Brand on Amazon.com 2Health News:OZ Naturals Now the No. 1 Selling Beauty Brand on Amazon.com 3Health News:Pitt team searches for genetic roots of cleft lip, palate 2Health News:BioMed Central to publish open access journal in collaboration with the University of Michigan 2Health News:Virginia Tech researchers discover potential biomarker to detect 'bubble boy' disorder 2Health News:Virginia Tech researchers discover potential biomarker to detect 'bubble boy' disorder 3Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2
... of Medicine in St. Louis claim that many children ... Their finding is totally reverse of the claims that ... said that 50 percent of the children who could ... ,"What we found was somewhat surprising," says Richard ...
... Young teenagers believe pregnancy would help them form connections ... boyfriend or creating a family of their own.// ... there are advantages in attaining motherhood early in life. ... the current issue of Pediatrics. ...
... from the University of Maryland School of Medicine, Galantamine, ... disease finds// a new role, in protecting people from ... The basis for further development of a safe and ... including nerve agents that have been used in chemical ...
... was launched in China on 7th August,2006//. ,Cancer is ... of Health department’s report in May. It accounts for ... and lifestyle factors are responsible for 80% of the cancers ... Treatment extends the lives of 60% of the cancer patients ...
... the Oman government's permission to carry out surgeries and ... group's new centre in the Omani capital Muscat. ... green signal to start our operation theatres, Intensive Care ... in the Times of Oman newspaper quoted V.T. Saileswaran ...
... compound derived from red algae to be a potent inhibitor ... warts//. The study has been published in the July ... thickening agent, blocks the Human Papillomavirus (HPV) from sticking to ... compound is a more natural and less expensive way to ...
Cached Medicine News:Health News:ADHD Children Are Being Under-Medicated 2Health News:ADHD Children Are Being Under-Medicated 3Health News:Teens and Pregnancy 2Health News:Teens and Pregnancy 3Health News:Alzheimer's Drug can be Used to Treat Nerve Agent and Pesticide Poisoning 2Health News:Alzheimer's Drug can be Used to Treat Nerve Agent and Pesticide Poisoning 3Health News:New Cancer-Blocking Algae Found 2
... A lower cost alternative to Equalizers, the ... transfers between two different vessel configurations. With the ... can be quickly and easily adjusted for test ... Ergonomic Design for Unparalleled Comfort Pick ...
... The Equalizer With 384 Well Plate ... the revolutionary features of the original Equalizerexpandable and ... autoclavable components, and in-lab calibration capabilities. In addition, ... tips down to 4.5mm for loading and accessing ...
Packaging: Set includes: Eight-channel pipette (10.8 mm with 0.5-5.0 μl capacity) 25 PrismStrip 96 tips with rack 2 FlexPlates with a holder...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
Medicine Products: